Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Selumetinib demonstrated an overall efficacy of 71.77% (95% CI (confidence interval): 63.24-81.45%) in late-stage/metastatic non-small cell lung cancer (NSCLC), with better efficacy when administered alone (74.08%) compared to combined therapy (65.20%). It also showed higher efficacy than chemo- or immune therapies, though this difference was not statistically significant.
• In neurofibromatosis type 1 (NF1)-associated tumors, selumetinib had a partial response rate of 68%-71% for inoperable or progressive plexiform neurofibromas in children 2 years and older. This was superior to the response rate of bevacizumab (36%-41%) for vestibular schwannomas in patients with neurofibromatosis type 2 (NF2).
• Selumetinib had an overall serious adverse event (SAE) rate of 42.96% (95% CI: 34.74-53.13%) in non-small cell lung cancer (NSCLC) patients. When used alone, selumetinib had a significantly better safety profile with an SAE rate of 10.49%, compared to 47.38% for combined therapy.
• Placebo Comparison: In the network meta-analysis for NSCLC, placebo had the best safety profile, followed by selumetinib, chemotherapy, and immune therapy.
• The NSCLC studies primarily involved older adults with a mean age of 62 years and a performance status (PS) of 0-2. For neurofibromatosis type 1 (NF1), the studies focused on children aged 2 years and older with inoperable or progressive plexiform neurofibromas. In neurofibromatosis type 2 (NF2), the studies included patients 12 years of age and older with vestibular schwannomas. There were no specific findings related to subgroups based on other demographic or clinical characteristics.